Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2244967 | 0.86 | CYP1A2 (0.44) | ALDH1A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL2240891 | 0.83 | NPC1 (0.48) | ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL2238514 | 0.83 | FFAR1 (0.49) | ALDH1A1SMN1; SMN2KDM4ENPC1TP53 | |
| SCHEMBL2238727 | 0.82 | NPC1 (0.52) | ALDH1A1CYP1A2CYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL2239687 | 0.81 | KDM4E (0.53) | CYP1A2SMN1; SMN2KDM4EGRM5ADORA3 | |
| SCHEMBL2241791 | 0.79 | PIP4K2A (0.47) | KDM4E | |
| SCHEMBL27572518 | 0.78 | NPC1 (0.72) | ALDH1A1SMN1; SMN2KDM4ENPC1TP53 | |
| SCHEMBL2241190 | 0.77 | KDM4E (0.46) | SMN1; SMN2KDM4ENPC1RAB9APKM | |
| SCHEMBL2237774 | 0.74 | KDM4E (0.45) | KDM4ERAB9AMAPTL3MBTL1LMNA | |
| SCHEMBL2240005 | 0.74 | KDM4E (0.47) | ALDH1A1CYP1A2CYP3A4SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | claimed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | claimed |
| EP-2044056-B1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2012-08-22 | — | — | EP | disclosed |
| US-7989458-B2 | Pyrimidine derivatives as alk-5 inhibitors | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | NOVARTIS AG (CH) | 2009-08-20 | — | — | US | disclosed |
| EP-2044056-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | Novartis Ag (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008006583-A1 | PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS | NOVARTIS AG (CH) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209539-A1 | Pyrimidine derivatives as alk-5 Inhibitors | ALK, ACVR1, MUSK | ALDH1A1 393/4885CYP1A2 929/4885CYP3A4 1519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.